Astrea Ocampo, the new president of the Mexican Association of Pharmaceutical Laboratories (AMELAF), has called on the government of Claudia Sheinbaum to prioritize the purchase of medications from Mexican pharmaceutical companies. She emphasized that there will be no financial aid or subsidies, yet urged the government to facilitate the procurement processes for local businesses that invest in the country. Ocampo highlighted that many of these companies rely heavily on public contracts to grow and reinvest in their operations.

In her address following her election as president for the 2026-2028 term, Ocampo reiterated that local pharmaceutical firms are strategic allies for the country's economic development, stressing their critical role in the national agenda. Over the past nine years, these manufacturers have made significant contributions to the local economy, but face challenges due to a lack of support and bureaucratic hurdles in government purchasing policies.

Ocampo's appeal underscores the broader conversation on the importance of supporting domestic industries amidst economic fluctuations and shifts in public policy. By advocating for local procurement, she positions the pharmaceutical sector as essential not only for healthcare accessibility but also for fostering economic resilience and innovation within the country.